Literature DB >> 9403590

Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients.

S Taddei1, A Virdis, L Ghiadoni, S Uleri, A Magagna, A Salvetti.   

Abstract

Essential hypertension is characterized by impaired endothelium-dependent vasodilation. The present study was designed to test whether antihypertensive treatment with the calcium antagonist lacidipine can improve endothelium-dependent vasodilation in essential hypertensive patients. In 12 normotensive subjects (mean age, 47.8+/-8.6 years; blood pressure, 118.6+/-4.2/76.7+/-3.9 mm Hg) and 19 hypertensive patients (mean age, 49.4+/-10.2 years; blood pressure; 153.5+/-13.3/101.3+/-6.4 mm Hg), we studied forearm blood flow modifications (strain-gauge plethysmography) induced by intrabrachial infusion of acetylcholine (0.15, 0.45, 1.5, 4.5, and 15 microg/100 mL per minute) and bradykinin (5, 15, and 50 ng/100 mL per minute), two endothelium-dependent vasodilators that act through different receptors and signal transduction pathways, and sodium nitroprusside (1, 2, and 4 microg/100 mL per minute), an endothelium-independent vasodilator. In essential hypertensive patients, vascular reactivity was repeated during prolonged (8 weeks of oral treatment at 6 mg/d) lacidipine administration and 2 weeks after withdrawal of chronic (32-week) treatment. Hypertensive patients showed significantly (P<.01) blunted vasodilation in response to acetylcholine (vascular resistance, 31.5+/-4.9 to 7.6+/-2.4 SU) and bradykinin (vascular resistance, 32.3+/-5.8 to 8.5+/-3.0 SU) compared with control subjects (vascular resistance: acetylcholine, 24.3+/-3.9 to 3.7+/-1.2 SU; bradykinin, 24.7+/-0.4 to 4.1+/-1.3 SU), whereas the response to sodium nitroprusside was similar. After either 8 or 32 weeks of lacidipine treatment, the vasodilation in response to acetylcholine (30.6+/-7.7 to 5.7+/-1.5 and 34.3+/-6.6 to 5.9+/-1.9 SU, respectively) and bradykinin (31.3+/-7.2 to 6.4+/-1.6 and 33.7+/-5.4 to 6.1+/-1.5 SU, respectively), but not to sodium nitroprusside, proved to be significantly (P<.05) increased compared with baseline. In essential hypertensive patients, oral treatment with lacidipine increased forearm vasodilation in response to acetylcholine and bradykinin, suggesting that this drug can improve endothelial function in patients with essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9403590     DOI: 10.1161/01.hyp.30.6.1606

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  22 in total

Review 1.  Effects of antihypertensive drugs on endothelial dysfunction: clinical implications.

Authors:  Stefano Taddei; Agostino Virdis; Lorenzo Ghiadoni; Isabella Sudano; Antonio Salvetti
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Effects of antihypertensive treatment on endothelial function.

Authors:  Agostino Virdis; Lorenzo Ghiadoni; Stefano Taddei
Journal:  Curr Hypertens Rep       Date:  2011-08       Impact factor: 5.369

3.  Cilnidipine, a slow-acting Ca2+ channel blocker, induces relaxation in porcine coronary artery: role of endothelial nitric oxide and [Ca2+]i.

Authors:  Hok Sum Leung; Xiaoqiang Yao; Fung Ping Leung; Wing Hung Ko; Zhen-Yu Chen; Maik Gollasch; Yu Huang
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 4.  Renal protection and antihypertensive drugs: current status.

Authors:  A Salvetti; P Mattei; I Sudano
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

Review 5.  Treating coronary disease and the impact of endothelial dysfunction.

Authors:  Yasushi Matsuzawa; Raviteja R Guddeti; Taek-Geun Kwon; Lilach O Lerman; Amir Lerman
Journal:  Prog Cardiovasc Dis       Date:  2014-10-22       Impact factor: 8.194

Review 6.  Current therapeutic strategies to mitigate the eNOS dysfunction in ischaemic stroke.

Authors:  Kirtiman Srivastava; Philip M W Bath; Ulvi Bayraktutan
Journal:  Cell Mol Neurobiol       Date:  2011-12-25       Impact factor: 5.046

Review 7.  Antihypertensive drugs and reversing of endothelial dysfunction in hypertension.

Authors:  S Taddei; A Virdis; L Ghiadoni; I Sudano; A Salvetti
Journal:  Curr Hypertens Rep       Date:  2000-02       Impact factor: 5.369

Review 8.  Drug Treatment of Hypertension: Focus on Vascular Health.

Authors:  Alan C Cameron; Ninian N Lang; Rhian M Touyz
Journal:  Drugs       Date:  2016-10       Impact factor: 9.546

Review 9.  Systemic Hypertension at High Altitude.

Authors:  Offdan Narvaez-Guerra; Karela Herrera-Enriquez; Josefina Medina-Lezama; Julio A Chirinos
Journal:  Hypertension       Date:  2018-09       Impact factor: 10.190

10.  VASCULAR INFLAMMATION AND ATHEROGENESIS ARE ACTIVATED VIA RECEPTORS FOR PAMPs AND SUPPRESSED BY REGULATORY T CELLS.

Authors:  Xiao-Feng Yang; Ying Yin; Hong Wang
Journal:  Drug Discov Today Ther Strateg       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.